Free
Pain Medicine  |   August 2001
Effects of Sevoflurane on Excitatory Neurotransmission to Medullary Expiratory Neurons and on Phrenic Nerve Activity in a Decerebrate Dog Model
Author Affiliations & Notes
  • Astrid G. Stucke, M.D.
    *
  • Eckehard A. E. Stuth, M.D.
  • Viseslav Tonkovic-Capin, M.D.
    *
  • Mislav Tonkovic-Capin, M.D.
  • Francis A. Hopp, M.S.
    §
  • John P. Kampine, M.D., Ph.D.
    ‖‖
  • Edward J. Zuperku, Ph.D.
    #
  • * Research Fellow in Anesthesiology, † Associate Professor of Anesthesiology, ‡ Assistant Professor of Anesthesiology, § Biomedical Engineer, ‖‖ Professor and Chairman of Anesthesiology, # Research Professor of Anesthesiology, Department of Anesthesiology.
  • Received from the Department of Anesthesiology, Medical College of Wisconsin, Children’s Hospital of Wisconsin, and the Zablocki VA Medical Center, Milwaukee, Wisconsin.
Article Information
Pain Medicine
Pain Medicine   |   August 2001
Effects of Sevoflurane on Excitatory Neurotransmission to Medullary Expiratory Neurons and on Phrenic Nerve Activity in a Decerebrate Dog Model
Anesthesiology 8 2001, Vol.95, 485-491. doi:
Anesthesiology 8 2001, Vol.95, 485-491. doi:
SEVOFLURANE  is a volatile anesthetic of the ether group that has only recently gained wide clinical acceptance. In vitro  studies demonstrate similarities between volatile anesthetics with respect to effects on synaptic neurotransmission but have also shown differences. For example, sevoflurane causes an open channel block of the γ-aminobutyric acid type A (GABAA) receptor that seems different from other volatile anesthetics. 1 
In neuraxis-intact mammals, anesthetic concentrations of sevoflurane appear to cause more depression of the respiratory centers and normoxic ventilation than halothane. 2 Preliminary data in humans have suggested that sevoflurane and halothane might affect subgroups of respiratory neurons differently. 3 
Our canine decerebrate preparation 4 allows the study of the effects of volatile anesthetics on synaptic neurotransmission to single brainstem respiratory neurons in vivo.  In previous studies, we found in the hyperoxic, vagotomized, and neuraxis-intact as well as in the decerebrate dog that the excitatory drive of expiratory premotor neurons in the caudal ventral respiratory group is primarily mediated by N  -methyl-d-aspartatic acid (NMDA) receptors, 5 whereas the main synaptic modulator of neuronal activity is a GABAAergic inhibitory input. 6 We recently reported the effects of halothane on GABAergic and glutamatergic neurotransmission using this model. 7 
The current study was conducted to elucidate the effects of sevoflurane on overall inhibitory (i.e.,  GABAAergic) and overall excitatory (i.e.,  glutamatergic) neurotransmission to expiratory premotor neurons. Furthermore, we determined the effect of sevoflurane on postsynaptic glutamatergic receptor function. In addition to analyzing the effects at the premotor level, we measured the effects of sevoflurane on peak phrenic activity. These sevoflurane data were then compared with recently reported halothane data. 7 
Materials and Methods
Animal Preparation and General Methodology
The research was approved by the Medical College of Wisconsin Animal Care Committee (Milwaukee, WI) and conformed with standards set forth in the National Institutes of Health Guide for Care and Use of Laboratory Animals.
Anesthesia in dogs was induced by mask ventilation with sevoflurane, and the trachea was intubated with a cuffed endotracheal tube; from that time, the lungs were mechanically ventilated with an oxygen–sevoflurane (1.3–1.8 minimum alveolar concentration [MAC]) mixture throughout the surgical procedures. We have previously described the surgical preparation in detail. 7,8 In short, after bilateral vagotomy and bilateral pneumothorax the animals were decerebrated 9 and paralyzed (0.1 mg/kg pancuronium followed by 0.1 mg · kg1· h1). The medulla oblongata and the phrenic nerve were prepared for recording. Esophageal temperature was maintained at 38.5 ± 1°C. Mean arterial pressure was kept above approximately 100 mmHg (if necessary, with 0.5–5 μg · kg1· min1phenylephrine). Protocols were performed only during steady-state conditions for blood pressure.
Neuron Recording Technique, Data Collection, and Experimental Conditions
Data recording and collection, as well as the drugs used, are described in detail in our previous study. 7 A multibarrel compound glass electrode was used to simultaneously record extracellular neuronal action potential activity before and during pressure ejection of respective neurotransmitters onto expiratory neurons of the caudal ventral respiratory group. 5,6,8 Bipolar hook electrodes were used to record multifiber activity from the C5 rootlet, and the phrenic neurogram was obtained from the moving average of this activity.
The protocols were performed under hyperoxic (fraction of inspired oxygen [Fio2] > 0.8) and steady-state hypercapnic conditions (arterial carbon dioxide tension, 50–60 mmHg). A typical protocol consisted of two separate picoejection periods (part 1, 200 μm NMDA; part 2, 200 μm bicuculline) at each anesthetic dose level (i.e.,  0 MAC, 1 MAC sevoflurane, and 0 MAC end control).
Picoejection Protocol, Part 1: Effects of Sevoflurane on Postsynaptic Glutamatergic Excitation
The peak neuronal discharge frequency (Fn) was measured for 10–20 respiratory cycles during a preejection control period (Fcon). Then the glutamate receptor agonist NMDA was applied in increasing dose rates until an increase in peak Fnof at least 40 Hz was achieved. Typically, picoejection durations of 6–8 min with 2 or 3 dose rates were needed. Sufficient time was allowed for Fnto return to the control level.
Statistical Analysis, Part 1
To quantify the effect of NMDA on the postsynaptic receptor, we determined the dose rate that caused a 40-Hz increase in peak Fn(i.e.,  a 40-Hz net increase at 0 MAC sevoflurane) and designated it as D40Hz. To confirm the linearity of the dose–response curves in this range, we also determined the net increase at half this dose rate and designated it as 1/2 D40Hz. Next, we determined the corresponding net increases from the dose–response curves at 1 MAC sevoflurane. Then all net increases were normalized to the 40-Hz net increase at 0 MAC, which was assigned a value of 100%. A two-way, repeated-measures analysis of variance with main factors of level of anesthesia (0 or 1 MAC sevoflurane) and neurotransmitter status (preejection control vs.  NMDA response) was performed (SuperANOVA; Abacus Concepts, Inc., Berkeley, CA).
Picoejection Protocol, Part 2: Effects of Sevoflurane on Overall Synaptic Neurotransmission
After recovery from NMDA, the GABAAreceptor antagonist bicuculline was picoejected until complete block of GABAAergic inhibition occurred (i.e.,  when an increase in picoejection dose rate did not result in any further increase in Fn). Typically, picoejection durations of 5–10 min with several increasing dose rates were required. Upon discontinuation of bicuculline, complete postejection recovery was awaited, which typically required 30–45 min. Then sevoflurane was introduced to a depth of 1.0 MAC (2.4 vol%), 10 and after an equilibration time of 15 min, both parts of the protocol were repeated in the same fashion. It was ensured that peak bicuculline dose rates during anesthesia always matched or exceeded those during the anesthetic-free run. After recovery from bicuculline, the anesthetic was discontinued, complete washout was awaited, and the picoejection protocol was repeated at 0 MAC to obtain end controls. A complete neuron protocol (0-MAC level, the anesthetic wash-in, the 1-MAC level, and the return to 0-MAC level end control) required approximately 4 h.
Statistical Analysis, Part 2
We defined the peak Fnfor the preejection control period as Fcon, and for the maximal Fnunder bicuculline block as Fe. Feis a measure of the uninhibited overall glutamatergic excitatory drive to the neuron, whereas Fconrepresents this drive reduced by the prevailing basal GABAAergic inhibition. To calculate the change in overall excitatory drive, the data were normalized to Feat the 0-MAC level, which was assigned a value of 100%. A two-way, repeated measures analysis of variance with main factors of level of anesthesia (0 or 1 MAC sevoflurane) and blocking status (preejection control vs.  maximal bicuculline block) was used.
The prevailing GABAAergic inhibition was described by the inhibitory constant α which is defined as follows:α=[Fe− Fcon]/Fe. The values for Feand Fconwere obtained for the 0-MAC level (Fcon0, Fe0) and the 1-MAC level (Fcon1, Fe1) from the experimental runs. Then they were used in the calculation of the anesthetic-induced effects on overall excitation (ΔFe=[Fe1− Fe0]/Fe0) and overall inhibition (Δα=[α1−α0]/α0). All results are given as mean ± SD, and P  < 0.05 was used to indicate significant differences unless stated otherwise.
Phrenic Nerve Data
Peak phrenic nerve activity (PPA), which is a neural index of the magnitude of the tidal volume, 11 was measured in arbitrary units as the peak height of the phrenic neurogram in the anesthetic-free control state and during steady-state 1 MAC sevoflurane anesthesia. PPA data obtained from our previously published halothane study were similarly analyzed for comparison purposes. All PPA data were normalized to the values obtained during the anesthetic-free control state, which was assigned a value of 100%. These normalized data were used in the subsequent statistical analyses to compare the two agents.
Results
Twenty animals were studied, and 16 complete neuron protocols consisting of 0-, 1-, and 0-MAC end control levels were obtained.
Protocol, Part 1: Effects of Sevoflurane on Postsynaptic Glutamatergic Excitation
Figure 1shows a representative example of an expiratory neuronal response to increasing picoejection dose rates of the glutamate receptor agonist NMDA before (trace A) and during (trace C) 1 MAC sevoflurane. A detailed analysis of these runs revealed that at 0 MAC a 40-Hz net increase was reached at a dose rate of 0.72 pmol/min. The net increase at the same dose rate at 1 MAC sevoflurane was 43.8 Hz even though Fconwas profoundly depressed from 115 to 35 Hz (i.e.,  by 70%).
Fig. 1. Response of an expiratory neuron to picoejection of the glutamate receptor agonist N  -methyl-d-aspartatic acid (NMDA; traces A and C ) and of the γ-aminobutyric acid type A receptor antagonist bicuculline (BIC; traces B  and D  ) at 0 and 1 minimum alveolar concentration (MAC) sevoflurane. The picoejection response curves are shown as the rate-meter recordings of the neuronal discharge frequency Fn. The duration of the picoejection and the maximally ejected dose rate are marked. The traces a  and b  show time expanded views of two rate meter recordings (a  , bottom  , and b  , bottom  ), together with the simultaneously recorded phrenic neurogram (PNG; in arbitrary units [a.u.]) and neuronal activity (N.A.). The detailed views are taken from the preejection control period (a  ) and at maximal increase of the neuronal discharge frequency (b  ). Also, note the increase in breathing frequency under 1 MAC sevoflurane (traces A  and B  vs.  C  and D  ).
Fig. 1. Response of an expiratory neuron to picoejection of the glutamate receptor agonist N 
	-methyl-d-aspartatic acid (NMDA; traces A and C ) and of the γ-aminobutyric acid type A receptor antagonist bicuculline (BIC; traces B 
	and D 
	) at 0 and 1 minimum alveolar concentration (MAC) sevoflurane. The picoejection response curves are shown as the rate-meter recordings of the neuronal discharge frequency Fn. The duration of the picoejection and the maximally ejected dose rate are marked. The traces a 
	and b 
	show time expanded views of two rate meter recordings (a 
	, bottom 
	, and b 
	, bottom 
	), together with the simultaneously recorded phrenic neurogram (PNG; in arbitrary units [a.u.]) and neuronal activity (N.A.). The detailed views are taken from the preejection control period (a 
	) and at maximal increase of the neuronal discharge frequency (b 
	). Also, note the increase in breathing frequency under 1 MAC sevoflurane (traces A 
	and B  vs.  C 
	and D 
	).
Fig. 1. Response of an expiratory neuron to picoejection of the glutamate receptor agonist N  -methyl-d-aspartatic acid (NMDA; traces A and C ) and of the γ-aminobutyric acid type A receptor antagonist bicuculline (BIC; traces B  and D  ) at 0 and 1 minimum alveolar concentration (MAC) sevoflurane. The picoejection response curves are shown as the rate-meter recordings of the neuronal discharge frequency Fn. The duration of the picoejection and the maximally ejected dose rate are marked. The traces a  and b  show time expanded views of two rate meter recordings (a  , bottom  , and b  , bottom  ), together with the simultaneously recorded phrenic neurogram (PNG; in arbitrary units [a.u.]) and neuronal activity (N.A.). The detailed views are taken from the preejection control period (a  ) and at maximal increase of the neuronal discharge frequency (b  ). Also, note the increase in breathing frequency under 1 MAC sevoflurane (traces A  and B  vs.  C  and D  ).
×
The pooled normalized net increases in peak Fn, which were produced by NMDA, for 16 complete neuron protocols are summarized in figure 2. One MAC sevoflurane reduced the NMDA-induced net increase from 100 to 82.3 ± 53.7% at D40Hz, but this was not statistically significant (P  = 0.17). The 0-MAC end control value for D40Hz(filled square in fig. 2) was 88.3 ± 53.6%, which was also not significantly different from the 0-MAC control (filled circle in fig. 2). The corresponding normalized 1/2 D40Hzdata were not statistically different. A slope analysis for the 0–1/2 D40Hzand the 1/2 D40Hz–D40Hzvalues confirmed linearity of the NMDA responses over the full dose range.
Fig. 2. Pooled summary data for protocol part 1, postsynaptic N  -methyl-d-aspartatic acid (NMDA) response. Normalized mean values ± SD of net increase of peak Fnat the NMDA dose rates 1/2 D40Hzand D40Hzfor 0-, 1-, and 0-minimum alveolar concentration (MAC) end control level (net increase = Fnat given NMDA dose rate − Fcon). The values are normalized to the D40Hznet increase at 0 MAC. At 1 MAC sevoflurane, the NMDA-induced net increase was nonsignificantly reduced from 100 to 82.3 ± 53.7% (n.s.; data staggered for clarity).
Fig. 2. Pooled summary data for protocol part 1, postsynaptic N 
	-methyl-d-aspartatic acid (NMDA) response. Normalized mean values ± SD of net increase of peak Fnat the NMDA dose rates 1/2 D40Hzand D40Hzfor 0-, 1-, and 0-minimum alveolar concentration (MAC) end control level (net increase = Fnat given NMDA dose rate − Fcon). The values are normalized to the D40Hznet increase at 0 MAC. At 1 MAC sevoflurane, the NMDA-induced net increase was nonsignificantly reduced from 100 to 82.3 ± 53.7% (n.s.; data staggered for clarity).
Fig. 2. Pooled summary data for protocol part 1, postsynaptic N  -methyl-d-aspartatic acid (NMDA) response. Normalized mean values ± SD of net increase of peak Fnat the NMDA dose rates 1/2 D40Hzand D40Hzfor 0-, 1-, and 0-minimum alveolar concentration (MAC) end control level (net increase = Fnat given NMDA dose rate − Fcon). The values are normalized to the D40Hznet increase at 0 MAC. At 1 MAC sevoflurane, the NMDA-induced net increase was nonsignificantly reduced from 100 to 82.3 ± 53.7% (n.s.; data staggered for clarity).
×
Part 2: Effects of Sevoflurane on Overall Synaptic Neurotransmission
Figure 1(traces B and D) shows the effects of bicuculline ejection on the same neuron as described earlier in this study for the NMDA responses. At 0 MAC, bicuculline increased peak Fnfrom 115 to 247 Hz, yielding a GABAAergic inhibitory constant α0= 0.53. This means that the prevailing endogenous GABAAergic inhibition attenuated neuronal output by 53% during the control state. At 1 MAC, bicuculline increased peak Fnfrom 35 to 162 Hz, yielding an α1value of 0.79. Thus, for this neuron, 1 MAC sevoflurane enhanced the GABAergic inhibition by 49%. The overall excitatory drive, which was measured in the absence of GABAAergic inhibition (i.e.,  during maximal block with bicuculline) was decreased from 247 to 162 Hz or by 34%.
The pooled data for 16 complete neuron protocols are shown in figure 3. Analysis of the pooled data shows that 1 MAC sevoflurane increased the mean α value from 0.47 ± 0.07 to 0.56 ± 0.11 (i.e.,  1 MAC sevo-flurane enhanced overall GABAAergic inhibition by 18.7 ± 20.6% (Δα, fig. 3,bottom  , center bar). At the same time, 1 MAC sevoflurane depressed overall excitation by 19.5 ± 16.2% (P  < 0.01, ΔFe, fig. 3, bottom  , left). In addition, peak Fconwas significantly reduced from 53.0 ± 6.4 to 36.6 ± 11.9% (fig. 3, top  , Fcon) (i.e.,  by 26.7 ± 22.4%[ΔFcon, fig. 3, bottom  , right).
Fig. 3. Pooled summary data for protocol part 2, bicuculline (BIC) response. (Top  ) Mean values ± SD of normalized peak Fn(%) before (Fcon) and during (Fe) maximal GABAAergic block with bicuculline for the 0-, 1- and 0-minimum alveolar concentration (MAC) end control level. At all MAC levels, Fewas significantly greater than Fcon(***P  < 0.001). 1 MAC sevoflurane caused a significant reduction of Fcon(§§§P  < 0.001) and Fe(###P  < 0.001). The 0 MAC end control values for Fconand Fewere not significantly different (n.s.) from the initial 0 MAC values, indicating stability and reproducibility of the preparation. (Bottom  ) Mean values ± SD for depression of overall excitatory drive, ΔFe, enhancement of inhibitory neurotransmission, Δα, and the resulting depression of control frequency, ΔFcon, by 1 MAC sevoflurane in 16 neurons (†P  < 0.01; ‡P  < 0.001, relative to no change).
Fig. 3. Pooled summary data for protocol part 2, bicuculline (BIC) response. (Top 
	) Mean values ± SD of normalized peak Fn(%) before (Fcon) and during (Fe) maximal GABAAergic block with bicuculline for the 0-, 1- and 0-minimum alveolar concentration (MAC) end control level. At all MAC levels, Fewas significantly greater than Fcon(***P 
	< 0.001). 1 MAC sevoflurane caused a significant reduction of Fcon(§§§P 
	< 0.001) and Fe(###P 
	< 0.001). The 0 MAC end control values for Fconand Fewere not significantly different (n.s.) from the initial 0 MAC values, indicating stability and reproducibility of the preparation. (Bottom 
	) Mean values ± SD for depression of overall excitatory drive, ΔFe, enhancement of inhibitory neurotransmission, Δα, and the resulting depression of control frequency, ΔFcon, by 1 MAC sevoflurane in 16 neurons (†P 
	< 0.01; ‡P 
	< 0.001, relative to no change).
Fig. 3. Pooled summary data for protocol part 2, bicuculline (BIC) response. (Top  ) Mean values ± SD of normalized peak Fn(%) before (Fcon) and during (Fe) maximal GABAAergic block with bicuculline for the 0-, 1- and 0-minimum alveolar concentration (MAC) end control level. At all MAC levels, Fewas significantly greater than Fcon(***P  < 0.001). 1 MAC sevoflurane caused a significant reduction of Fcon(§§§P  < 0.001) and Fe(###P  < 0.001). The 0 MAC end control values for Fconand Fewere not significantly different (n.s.) from the initial 0 MAC values, indicating stability and reproducibility of the preparation. (Bottom  ) Mean values ± SD for depression of overall excitatory drive, ΔFe, enhancement of inhibitory neurotransmission, Δα, and the resulting depression of control frequency, ΔFcon, by 1 MAC sevoflurane in 16 neurons (†P  < 0.01; ‡P  < 0.001, relative to no change).
×
Effects of Sevoflurane and Halothane on Fconand on Phrenic Activity
Phrenic data 1were used when peak phrenic amplitude (PPA) for the 0-MAC end control period recovered to the preanesthesia control level. To maximize the number of data sets, we used phrenic data from several related studies with the same experimental setup (decerebration, mechanical ventilation, hyperoxic hypercapnia) and the same anesthetic sequence (0 MAC, 1 MAC, 0 MAC) but divergent picoejection protocols. We analyzed 20 protocols with sevoflurane, which were derived from 28 animals from the current study and an ongoing study. Twenty-four data sets with halothane were derived from 36 dogs, also from two studies (a study of halothane and expiratory neurons 7 and an ongoing study).
Both anesthetics significantly reduced PPA (fig. 4,right  ). Sevoflurane reduced PPA significantly more than halothane (60.1 ± 17.6%vs.  42.5 ± 18.4%, P  < 0.01, unpaired two-sided t  test). Both anesthetics depressed expiratory neuronal activity to a similar extent (ΔFcon[sevoflurane], 26.7 ± 22.4%vs.  ΔFcon[halothane], 27.9 ± 10.6%7 (fig. 4, left  , nonsignificant). Both anesthetics depressed PPA significantly more than Fcon(sevoflurane, P  < 0.001; halothane, P  < 0.01 [unpaired two-sided t  test).
Fig. 4. Comparative effects of 1 minimum alveolar concentration (MAC) sevoflurane (SEVO; current study) and 1 MAC halothane 7 (HAL) on peak expiratory neuronal activity (ΔFcon, left bars  ) and peak phrenic nerve activity (ΔPPA (right bars  ). The depression of Fconby 1 MAC sevoflurane was not different (n.s.) from the depression by 1 MAC halothane. The depression of PPA by the anesthetic was significantly larger than the depression of Fcon, both for 1 MAC halothane (##P  < 0.01) and for 1 MAC sevoflurane (§§§P  < 0.001). In addition, the depression of PPA was significantly larger with 1 MAC sevoflurane than with 1 MAC halothane (**P  < 0.01).
Fig. 4. Comparative effects of 1 minimum alveolar concentration (MAC) sevoflurane (SEVO; current study) and 1 MAC halothane 7(HAL) on peak expiratory neuronal activity (ΔFcon, left bars 
	) and peak phrenic nerve activity (ΔPPA (right bars 
	). The depression of Fconby 1 MAC sevoflurane was not different (n.s.) from the depression by 1 MAC halothane. The depression of PPA by the anesthetic was significantly larger than the depression of Fcon, both for 1 MAC halothane (##P 
	< 0.01) and for 1 MAC sevoflurane (§§§P 
	< 0.001). In addition, the depression of PPA was significantly larger with 1 MAC sevoflurane than with 1 MAC halothane (**P 
	< 0.01).
Fig. 4. Comparative effects of 1 minimum alveolar concentration (MAC) sevoflurane (SEVO; current study) and 1 MAC halothane 7 (HAL) on peak expiratory neuronal activity (ΔFcon, left bars  ) and peak phrenic nerve activity (ΔPPA (right bars  ). The depression of Fconby 1 MAC sevoflurane was not different (n.s.) from the depression by 1 MAC halothane. The depression of PPA by the anesthetic was significantly larger than the depression of Fcon, both for 1 MAC halothane (##P  < 0.01) and for 1 MAC sevoflurane (§§§P  < 0.001). In addition, the depression of PPA was significantly larger with 1 MAC sevoflurane than with 1 MAC halothane (**P  < 0.01).
×
Discussion
The current study shows that sevoflurane reduced the activity of expiratory premotor neurons in the brainstem of decerebrate dogs. This reduction resulted from a depression of glutamatergic excitation without affecting the postsynaptic glutamate receptor excitability. Enhancement of GABAAergic inhibitory neurotransmission contributed approximately equally to the depressant effect of sevoflurane. The current study cannot address whether the GABAAergic effects are presynaptic or postsynaptic in nature.
The magnitude of the reduction of overall glutamatergic excitation by sevoflurane was not different than that found previously for halothane (P  = 0.08, unpaired two-sided t  test) 7 . Thus, it is likely that both anesthetics affect similar mechanisms that result in the inhibition of presynaptic glutamate release. These mechanisms may include a reduction in excitatory drive to the presynaptic neurons, as it has been described by Perouansky et al.  12 for the excitation of inhibitory interneurons, and inhibitory effects on one or more steps in the cascade that controls exocytosis of glutamate. 13 
Our in vivo  study showed an enhancement of overall GABAAergic inhibition by 1 MAC sevoflurane, although we could not apportion the amount of presynaptic and postsynaptic contributions. Additional studies would be necessary to delineate the effects of sevoflurane and halothane on the postsynaptic GABAAreceptor function in our respiratory neuron model.
An enhancement of the response to GABA and a small direct activation by sevoflurane have been described for the GABAAreceptor. 1,14 In acutely dissociated rat hippocampal neurons during whole cell voltage clamp, Kira et al.  1 showed that sevoflurane alone could increase the Clcurrent (ICl). However, this effect is negligible at 1 MAC sevoflurane (i.e.,  0.35-mm concentration 15) in aqueous solution and only becomes noticeable at bath concentrations of 3 MAC and greater. At 1 MAC, sevoflurane not only enhanced the GABA-induced ICl, 14 but also accelerated the activation phase of ICl, suggesting an increase in the apparent affinity of the GABAAreceptor to GABA. 1 Similarly, whole cell patch-clamp studies by Jenkins et al.  16 on mouse fibroblasts transfected with GABAAreceptor subunits suggested a direct binding of sevoflurane to the receptor channel protein. In addition, the authors reported that there was no difference in the degree of GABAAergic potentiation between sevoflurane and halothane at 37°C. In accordance, we also found that there was no difference between the enhancement of overall inhibition by 1 MAC sevoflurane and 1 MAC halothane 7 in expiratory premotor neurons (P  = 0.18, unpaired two-sided t  test).
The phrenic neurogram represents the collective neuronal output of the phrenic motoneuron pool, and PPA is considered to be a good neural index for the magnitude of tidal volume. 11 Our data show that PPA is more depressed than expiratory premotor neurons (fig. 4). This suggests either a differential depression of inspiratory and expiratory premotor neurons by the anesthetics or additional depressant effects downstream at the phrenic motoneuronal level. However, we could show in an intact preparation that a 1-MAC halothane increase (from 1 to 2 MAC) depressed inspiratory and expiratory premotor neuronal activity to the same extent and significantly less than PPA. 17 Similarly, in the decerebrate preparation halothane depressed PPA more than expiratory premotor neuron activity. We assume that this differential depression is in part caused by an additional anesthetic-induced depression of synaptic transmission from the bulbospinal premotor neurons to the phrenic motoneurons, as well as direct depression of the phrenic motoneurons.
Recent in vitro  studies have suggested the presence of voltage-independent, hyperpolarizing leak K+channels that are activated by inhalational anesthetics 18 and can be found in cerebral nuclei and with an especially high density in the membrane of motoneurons in the brainstem and spinal cord. 19 Talley et al.  19 found that in rat hypoglossal motoneurons tandem-pore domain acid-sensitive K+(TASK)-1 channels contributed to a prominent pH-sensitive background K+current. Both halothane and sevoflurane increased the conductance of these K+channels, which produced dose-dependent hyperpolarizations that could be antagonized by decreasing the pH from 7.3 to 6.5. 20 It is possible that such anesthesia-induced K+channels contribute to the pronounced depression of phrenic motoneurons compared with the expiratory premotor neurons in our study.
Interestingly, Sirois et al. 18 found in hypoglossal motoneurons in a neonatal rat brainstem slice preparation that the outward K+current induced by 0.75% halothane (51.1 ± 6.5 pA) was 40% less than the current induced by 2.0% sevoflurane (71.3 ± 8.8 pA), which are considered equivalent anesthetic concentrations. These values suggest that sevoflurane may have a greater effect on TASK-1 channels than halothane. This could explain the finding that, in our preparation, at the 1-MAC level sevoflurane depressed phrenic motoneurons to a greater extent than halothane.
A similar, differential effect for the two anesthetics was reported by Doi et al.,  2 who recorded respiratory-related neuronal activity in the feline nucleus ambiguus and found a significantly greater depression of spontaneous neuronal activity with 1 MAC sevoflurane than with 1 MAC halothane. The nucleus ambiguus contains a high number of respiratory-related laryngeal and pharyngeal motoneurons, 21 and labeling reveals a high density of TASK-1 channels in this area. 19 We consider it likely that the neuron sample of Doi et al.,  2 contained mainly motoneurons and speculate that the greater depression of neuronal activity by sevoflurane was caused by a differential effect on TASK-1 channels.
TASK-1 transcripts are expressed at high levels in cranial and spinal motoneurons but not in all neurons. The role of these channels may be minimal in our premotor neurons, although direct data are lacking. Because activation of these channels was capable of producing up to a 50% increase in whole cell membrane conductance in hypoglossal motoneurons, 20 this effect would reduce neuronal excitability. However, the NMDA-induced excitation of our expiratory premotor neurons was not altered by sevoflurane (fig. 2) or halothane. 7 In addition, TASK-1 channels have been shown to be depressed by low pH, serotonin, and norepinephrine. 19 Ejection of serotonin, norepinephrine, and acidified artificial cerebrospinal fluid on expiratory premotor neurons in the thiopental-anesthetized intact dog does not alter neuronal frequency (unpublished data) as would be expected if TASK-1 channels were present and functional. Thus, it seems unlikely that in these canine expiratory premotor neurons an anesthetic-induced activation of inhibitory K+channels contributed to the changes in excitatory drive (i.e.,  the depression of overall excitation).
Methodological Considerations
Many of the limitations of our methodology have been discussed in our previous publications 7,8 and elsewhere. 6,7 Decerebration allowed us to compare the effect of 1 MAC sevoflurane with an anesthesia-free control state. This may explain differences between our results and other studies. Mutoh et al.  22 studied the effect of sevoflurane on respiratory parameters in intact dogs under α-chloralose–urethane background anesthesia and also found that sevoflurane induced an increase in breathing frequency. In their model, however, this effect of sevoflurane could be abolished by vagotomy. In our decerebrate, vagotomized, and peripherally deafferented dogs sevoflurane still caused an increase in breathing frequency. Thus, we suggest that sevoflurane, like halothane, also has directly stimulating effects at the brainstem level, presumably in the rate-generating regions. 23 
In summary, sevoflurane depressed expiratory premotor neuron activity through a presynaptic reduction of glutamatergic excitation and an enhancement of GABAAergic inhibition. Sevoflurane depressed expiratory premotor neurons significantly less than phrenic motoneurons.
The authors thank Jack Tomlinson, Biology Laboratory Technician, Department of Anesthesiology, VA Medical Center, Milwaukee, Wisconsin, for excellent technical assistance.
References
Kira T, Harata N, Sakata T, Akaike N: Kinetics of sevoflurane action on GABA- and glycine-induced currents in acutely dissociated rat hippocampal neurons. Neuroscience 1998; 85: 383–94Kira, T Harata, N Sakata, T Akaike, N
Doi K, Kasaba T, Kosaka Y: A comparative study of the depressive effects of halothane and sevoflurane on medullary respiratory neuron in cats. Masui 1988; 37: 1466–77Doi, K Kasaba, T Kosaka, Y
Brown K, Aun C, Stocks J, Jackson E, Mackersie A, Hatch D: A comparison of the respiratory effects of sevoflurane and halothane in infants and young children. A nesthesiology 1998; 89: 86–92Brown, K Aun, C Stocks, J Jackson, E Mackersie, A Hatch, D
McCrimmon DR, Zuperku EJ, Hayashi F, Dogas Z, Hinrichsen CFL, Stuth EA, Tonkovic-Capin M, Krolo M, Hopp FA: Modulation of the synaptic drive to respiratory premotor and motor neurons. Respir Physiol 1997; 110: 161–76McCrimmon, DR Zuperku, EJ Hayashi, F Dogas, Z Hinrichsen, CFL Stuth, EA Tonkovic-Capin, M Krolo, M Hopp, FA
Dogas Z, Stuth EAE, Hopp FA, McCrimmon DR, Zuperku EJ: NMDA receptor-mediated transmission of carotid body chemoreceptor input to expiratory bulbospinal neurones in dogs. J Physiol (Lond) 1995; 487: 639–51Dogas, Z Stuth, EAE Hopp, FA McCrimmon, DR Zuperku, EJ
Dogas Z, Krolo M, Stuth EA, Tonkovic-Capin M, Hopp FA, McCrimmon DR, Zuperku EJ: Differential effects of GABAAreceptor antagonists in the control of respiratory neuronal discharge patterns. J Neurophysiol 1998; 80: 2368–77Dogas, Z Krolo, M Stuth, EA Tonkovic-Capin, M Hopp, FA McCrimmon, DR Zuperku, EJ
Stuth EAE, Krolo M, Stucke AG, Tonkovic-Capin M, Tonkovic-Capin V, Hopp FA, Kampine JP, Zuperku EJ: Effects of halothane on excitatory neurotransmission to medullary expiratory neurons in a decerebrate dog model. A nesthesiology 2000; 93: 1474–81Stuth, EAE Krolo, M Stucke, AG Tonkovic-Capin, M Tonkovic-Capin, V Hopp, FA Kampine, JP Zuperku, EJ
Stuth EAE, Krolo M, Tonkovic-Capin M, Hopp FA, Kampine JP, Zuperku EJ: Effects of halothane on synaptic neurotransmission to medullary expiratory neurons in the ventral respiratory group of dogs. A nesthesiology 1999; 91: 804–14Stuth, EAE Krolo, M Tonkovic-Capin, M Hopp, FA Kampine, JP Zuperku, EJ
Tonkovic-Capin M, Krolo M, Stuth EAE, Hopp FA, Zuperku EJ: Improved method of canine decerebration. J Appl Physiol 1998; 85: 747–50Tonkovic-Capin, M Krolo, M Stuth, EAE Hopp, FA Zuperku, EJ
Kazama T, Ikeda K: Comparison of MAC and the rate of rise of alveolar concentration of sevoflurane with halothane and isoflurane in the dog. A nesthesiology 1988; 68: 435–7Kazama, T Ikeda, K
Eldridge FL: Relationship between respiratory nerve and muscle activity and muscle force output. J Appl Physiol 1975; 39: 567–74Eldridge, FL
Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. A nesthesiology 1996; 85: 1431–8Perouansky, M Kirson, ED Yaari, Y
Schlame M, Hemmings HC: Inhibition by volatile anesthetics of endogenous glutamate release from synaptosomes by a presynaptic mechanism. A nesthesiology 1995; 82: 1406–16Schlame, M Hemmings, HC
Wu J, Harata N, Akaike N: Potentiation by sevoflurane of the g-aminobutyric acid-induced chloride current in acutely dissociated CA1 pyramidal neurones from rat hippocampus. Br J Pharmacol 1996; 119: 1013–21Wu, J Harata, N Akaike, N
Franks NP, Lieb WR: Temperature dependence of the potency of volatile anesthetics: Implications for in vitro experiments. A nesthesiology 1996; 84: 716–20Franks, NP Lieb, WR
Jenkins A, Franks NP, Lieb WR: Effects of temperature and volatile anesthetics on GABAAreceptors. A nesthesiology 1999; 90: 484–91Jenkins, A Franks, NP Lieb, WR
Stuth EAE, Tonkovic-Capin M, Kampine JP, Bajic J, Zuperku EJ: Dose-dependent effects of halothane on the carbon dioxide responses of expiratory and inspiratory bulbospinal neurons and the phrenic nerve activities in dogs. A nesthesiology 1994; 81: 1470–83Stuth, EAE Tonkovic-Capin, M Kampine, JP Bajic, J Zuperku, EJ
Sirois JE, Pancrazio JJ, Lynch C,III Bayliss DA: Multiple ionic mechanisms mediate inhibition of rat motoneurones by inhalation anaesthetics. J Physiol 1998; 512: 851–62Sirois, JE Pancrazio, JJ Lynch, C Bayliss, DA
Talley EM, Lei Q, Sirois JE, Bayliss DA: TASK-1, a two-pore domain K channel, is modulated by multiple neurotransmitters in motoneurons. Neuron 2000; 25: 399–410Talley, EM Lei, Q Sirois, JE Bayliss, DA
Sirois JE, Lie Q, Talley EM, Lynch C, III Bayliss DA: The TASK-1 two-pore domain K+channel is a molecular substrate for neuronal effects of inhalation anesthetics. J Neurosci 2000; 201: 6347–54Sirois, JE Lie, Q Talley, EM Lynch, C Bayliss, DA
Bianchi AL, Denavit-Saubie M, Champagnat J: Central control of breathing in mammals: Neuronal circuitry, membrane properties, and neurotransmitters. Physiol Rev 1995; 75: 1–45Bianchi, AL Denavit-Saubie, M Champagnat, J
Mutoh T, Tsubone H, Nishimura R, Sasaki N: Effects of volatile anesthetics on vagal C-fiber activities and their reflexes in anesthetized dogs. Respir Physiol 1998; 112: 253–64Mutoh, T Tsubone, H Nishimura, R Sasaki, N
Butera RJ Jr, Rinzel J, Smith JC: Models of respiratory rhythm generation in the pre-Bötzinger complex, II: Populations of coupled pacemaker neurons. J Neurophysiol 1999; 81: 398–415Butera, RJ Rinzel, J Smith, JC
Fig. 1. Response of an expiratory neuron to picoejection of the glutamate receptor agonist N  -methyl-d-aspartatic acid (NMDA; traces A and C ) and of the γ-aminobutyric acid type A receptor antagonist bicuculline (BIC; traces B  and D  ) at 0 and 1 minimum alveolar concentration (MAC) sevoflurane. The picoejection response curves are shown as the rate-meter recordings of the neuronal discharge frequency Fn. The duration of the picoejection and the maximally ejected dose rate are marked. The traces a  and b  show time expanded views of two rate meter recordings (a  , bottom  , and b  , bottom  ), together with the simultaneously recorded phrenic neurogram (PNG; in arbitrary units [a.u.]) and neuronal activity (N.A.). The detailed views are taken from the preejection control period (a  ) and at maximal increase of the neuronal discharge frequency (b  ). Also, note the increase in breathing frequency under 1 MAC sevoflurane (traces A  and B  vs.  C  and D  ).
Fig. 1. Response of an expiratory neuron to picoejection of the glutamate receptor agonist N 
	-methyl-d-aspartatic acid (NMDA; traces A and C ) and of the γ-aminobutyric acid type A receptor antagonist bicuculline (BIC; traces B 
	and D 
	) at 0 and 1 minimum alveolar concentration (MAC) sevoflurane. The picoejection response curves are shown as the rate-meter recordings of the neuronal discharge frequency Fn. The duration of the picoejection and the maximally ejected dose rate are marked. The traces a 
	and b 
	show time expanded views of two rate meter recordings (a 
	, bottom 
	, and b 
	, bottom 
	), together with the simultaneously recorded phrenic neurogram (PNG; in arbitrary units [a.u.]) and neuronal activity (N.A.). The detailed views are taken from the preejection control period (a 
	) and at maximal increase of the neuronal discharge frequency (b 
	). Also, note the increase in breathing frequency under 1 MAC sevoflurane (traces A 
	and B  vs.  C 
	and D 
	).
Fig. 1. Response of an expiratory neuron to picoejection of the glutamate receptor agonist N  -methyl-d-aspartatic acid (NMDA; traces A and C ) and of the γ-aminobutyric acid type A receptor antagonist bicuculline (BIC; traces B  and D  ) at 0 and 1 minimum alveolar concentration (MAC) sevoflurane. The picoejection response curves are shown as the rate-meter recordings of the neuronal discharge frequency Fn. The duration of the picoejection and the maximally ejected dose rate are marked. The traces a  and b  show time expanded views of two rate meter recordings (a  , bottom  , and b  , bottom  ), together with the simultaneously recorded phrenic neurogram (PNG; in arbitrary units [a.u.]) and neuronal activity (N.A.). The detailed views are taken from the preejection control period (a  ) and at maximal increase of the neuronal discharge frequency (b  ). Also, note the increase in breathing frequency under 1 MAC sevoflurane (traces A  and B  vs.  C  and D  ).
×
Fig. 2. Pooled summary data for protocol part 1, postsynaptic N  -methyl-d-aspartatic acid (NMDA) response. Normalized mean values ± SD of net increase of peak Fnat the NMDA dose rates 1/2 D40Hzand D40Hzfor 0-, 1-, and 0-minimum alveolar concentration (MAC) end control level (net increase = Fnat given NMDA dose rate − Fcon). The values are normalized to the D40Hznet increase at 0 MAC. At 1 MAC sevoflurane, the NMDA-induced net increase was nonsignificantly reduced from 100 to 82.3 ± 53.7% (n.s.; data staggered for clarity).
Fig. 2. Pooled summary data for protocol part 1, postsynaptic N 
	-methyl-d-aspartatic acid (NMDA) response. Normalized mean values ± SD of net increase of peak Fnat the NMDA dose rates 1/2 D40Hzand D40Hzfor 0-, 1-, and 0-minimum alveolar concentration (MAC) end control level (net increase = Fnat given NMDA dose rate − Fcon). The values are normalized to the D40Hznet increase at 0 MAC. At 1 MAC sevoflurane, the NMDA-induced net increase was nonsignificantly reduced from 100 to 82.3 ± 53.7% (n.s.; data staggered for clarity).
Fig. 2. Pooled summary data for protocol part 1, postsynaptic N  -methyl-d-aspartatic acid (NMDA) response. Normalized mean values ± SD of net increase of peak Fnat the NMDA dose rates 1/2 D40Hzand D40Hzfor 0-, 1-, and 0-minimum alveolar concentration (MAC) end control level (net increase = Fnat given NMDA dose rate − Fcon). The values are normalized to the D40Hznet increase at 0 MAC. At 1 MAC sevoflurane, the NMDA-induced net increase was nonsignificantly reduced from 100 to 82.3 ± 53.7% (n.s.; data staggered for clarity).
×
Fig. 3. Pooled summary data for protocol part 2, bicuculline (BIC) response. (Top  ) Mean values ± SD of normalized peak Fn(%) before (Fcon) and during (Fe) maximal GABAAergic block with bicuculline for the 0-, 1- and 0-minimum alveolar concentration (MAC) end control level. At all MAC levels, Fewas significantly greater than Fcon(***P  < 0.001). 1 MAC sevoflurane caused a significant reduction of Fcon(§§§P  < 0.001) and Fe(###P  < 0.001). The 0 MAC end control values for Fconand Fewere not significantly different (n.s.) from the initial 0 MAC values, indicating stability and reproducibility of the preparation. (Bottom  ) Mean values ± SD for depression of overall excitatory drive, ΔFe, enhancement of inhibitory neurotransmission, Δα, and the resulting depression of control frequency, ΔFcon, by 1 MAC sevoflurane in 16 neurons (†P  < 0.01; ‡P  < 0.001, relative to no change).
Fig. 3. Pooled summary data for protocol part 2, bicuculline (BIC) response. (Top 
	) Mean values ± SD of normalized peak Fn(%) before (Fcon) and during (Fe) maximal GABAAergic block with bicuculline for the 0-, 1- and 0-minimum alveolar concentration (MAC) end control level. At all MAC levels, Fewas significantly greater than Fcon(***P 
	< 0.001). 1 MAC sevoflurane caused a significant reduction of Fcon(§§§P 
	< 0.001) and Fe(###P 
	< 0.001). The 0 MAC end control values for Fconand Fewere not significantly different (n.s.) from the initial 0 MAC values, indicating stability and reproducibility of the preparation. (Bottom 
	) Mean values ± SD for depression of overall excitatory drive, ΔFe, enhancement of inhibitory neurotransmission, Δα, and the resulting depression of control frequency, ΔFcon, by 1 MAC sevoflurane in 16 neurons (†P 
	< 0.01; ‡P 
	< 0.001, relative to no change).
Fig. 3. Pooled summary data for protocol part 2, bicuculline (BIC) response. (Top  ) Mean values ± SD of normalized peak Fn(%) before (Fcon) and during (Fe) maximal GABAAergic block with bicuculline for the 0-, 1- and 0-minimum alveolar concentration (MAC) end control level. At all MAC levels, Fewas significantly greater than Fcon(***P  < 0.001). 1 MAC sevoflurane caused a significant reduction of Fcon(§§§P  < 0.001) and Fe(###P  < 0.001). The 0 MAC end control values for Fconand Fewere not significantly different (n.s.) from the initial 0 MAC values, indicating stability and reproducibility of the preparation. (Bottom  ) Mean values ± SD for depression of overall excitatory drive, ΔFe, enhancement of inhibitory neurotransmission, Δα, and the resulting depression of control frequency, ΔFcon, by 1 MAC sevoflurane in 16 neurons (†P  < 0.01; ‡P  < 0.001, relative to no change).
×
Fig. 4. Comparative effects of 1 minimum alveolar concentration (MAC) sevoflurane (SEVO; current study) and 1 MAC halothane 7 (HAL) on peak expiratory neuronal activity (ΔFcon, left bars  ) and peak phrenic nerve activity (ΔPPA (right bars  ). The depression of Fconby 1 MAC sevoflurane was not different (n.s.) from the depression by 1 MAC halothane. The depression of PPA by the anesthetic was significantly larger than the depression of Fcon, both for 1 MAC halothane (##P  < 0.01) and for 1 MAC sevoflurane (§§§P  < 0.001). In addition, the depression of PPA was significantly larger with 1 MAC sevoflurane than with 1 MAC halothane (**P  < 0.01).
Fig. 4. Comparative effects of 1 minimum alveolar concentration (MAC) sevoflurane (SEVO; current study) and 1 MAC halothane 7(HAL) on peak expiratory neuronal activity (ΔFcon, left bars 
	) and peak phrenic nerve activity (ΔPPA (right bars 
	). The depression of Fconby 1 MAC sevoflurane was not different (n.s.) from the depression by 1 MAC halothane. The depression of PPA by the anesthetic was significantly larger than the depression of Fcon, both for 1 MAC halothane (##P 
	< 0.01) and for 1 MAC sevoflurane (§§§P 
	< 0.001). In addition, the depression of PPA was significantly larger with 1 MAC sevoflurane than with 1 MAC halothane (**P 
	< 0.01).
Fig. 4. Comparative effects of 1 minimum alveolar concentration (MAC) sevoflurane (SEVO; current study) and 1 MAC halothane 7 (HAL) on peak expiratory neuronal activity (ΔFcon, left bars  ) and peak phrenic nerve activity (ΔPPA (right bars  ). The depression of Fconby 1 MAC sevoflurane was not different (n.s.) from the depression by 1 MAC halothane. The depression of PPA by the anesthetic was significantly larger than the depression of Fcon, both for 1 MAC halothane (##P  < 0.01) and for 1 MAC sevoflurane (§§§P  < 0.001). In addition, the depression of PPA was significantly larger with 1 MAC sevoflurane than with 1 MAC halothane (**P  < 0.01).
×